Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIke Study: nivolumab + ipilimumab with platinum-doublet chemotherapy for untreated brain metastases in advanced non-small cell lung cancer
jRCTs071210019Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- May 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab, ipilimumab, carboplatin, pemetrexed and paclitaxel in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Ono Pharmaceutical. Primary endpoint: Response rate of brain metastases. Started May 2021; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs071210019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071210019.